CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 123 enrolled
Drug / intervention
ADX-102 Ophthalmic Solution (0.5%) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03131154
NCT03131154Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis.

Aldeyra Therapeutics, Inc.·interventional·Posted Apr 27, 2017·Updated Feb 10, 2025

In Brief

A Phase 3 clinical trial evaluating ADX-102 Ophthalmic Solution (0.5%) and Vehicle of ADX-102 Ophthalmic Solution for Non-infectious Anterior Uveitis. Completed, enrolled 123 participants across 27 sites.

Detailed Summary

A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-infectious Anterior Uveitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedApr 27, 2017
Enrollment StartApr 26, 2017
Primary CompletionApr 19, 2019
Study CompletionApr 26, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.2 years ago

Interventions

ADX-102 Ophthalmic Solution (0.5%)drug

ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.

Vehicle of ADX-102 Ophthalmic Solutiondrug

Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.